Relationship between matrix metalloproteinase-9 and oxidative stress in drug-free male schizophrenia: a case control study
- 1 January 2016
- journal article
- research article
- Published by Walter de Gruyter GmbH in Clinical Chemistry and Laboratory Medicine (CCLM)
- Vol. 54 (3) , 447-452
Abstract
Background: Deregulation of synaptic plasticity and oxidative stress are reported to play a crucial role in the pathogenesis of schizophrenia. Matrix metalloproteinase-9 (MMP-9) is an extracellular protease involved in regulation of synaptic plasticity. Malondialdehyde (MDA) is a marker of lipid peroxidation which is elevated in schizophrenia. Earlier studies have reported polymorphism of MMP-9 and its association with schizophrenia. The present study was designed to assess the serum levels of MMP-9, MDA and total antioxidant status (TAS) and their association in schizophrenia. Methods: A total of 40 cases and 40 controls were included in the study. Serum MMP-9, MDA and TAS were estimated in all the subjects. Disease severity was assessed using Positive and Negative Syndrome Scale (PANSS). Results: MMP-9 and MDA were significantly increased and TAS were significantly reduced in schizophrenia cases compared to controls. MMP-9 was positively correlated with MDA (r=0.353, p=0.025) and negatively correlated with TAS (r=−0.461, p=0.003). TAS was significantly correlated with total (r=0.322, p=0.043) and negative symptom scores (r=0.336, p=0.034). Higher MMP-9 levels were associated with previous exposure to antipsychotics (p=0.032). Conclusions: MMP-9 and oxidative stress were increased and correlate well with each other in schizophrenia cases. Though total oxidant status showed positive association with disease severity, MMP-9 and MDA were not associated with the severity of the disease.Keywords
This publication has 10 references indexed in Scilit:
- Matrix Metalloproteinase-9: Many Shades of Function in Cardiovascular DiseasePhysiology, 2013
- Similarities in serum oxidative stress markers and inflammatory cytokines in patients with overt schizophrenia at early and late stages of chronicityJournal of Psychiatric Research, 2012
- Total antioxidant response in patients with schizophreniaPsychiatry and Clinical Neurosciences, 2006
- Decreased antioxidant enzymes and membrane essential polyunsaturated fatty acids in schizophrenic and bipolar mood disorder patientsPsychiatry Research, 2003
- Correlation of oxidative stress with activity of matrix metalloproteinase in patients with coronary artery disease Possible role for left ventricular remodellingEuropean Heart Journal, 2003
- Reduced erythrocyte membrane essential fatty acids and increased lipid peroxides in schizophrenia at the never-medicated first-episode of psychosis and after years of treatment with antipsychoticsSchizophrenia Research, 2002
- Oxidative stress and role of antioxidant and ω-3 essential fatty acid supplementation in schizophreniaProgress in Neuro-Psychopharmacology and Biological Psychiatry, 2001
- A simple, rapid, highly sensitive and reproducible quantification method for plasma malondialdehyde by high‐performance liquid chromatographyBiomedical Chromatography, 1998
- Reactive oxygen species produced by macrophage-derived foam cells regulate the activity of vascular matrix metalloproteinases in vitro. Implications for atherosclerotic plaque stability.Journal of Clinical Investigation, 1996
- Regulation of Matrix Metalloproteinase Expression in Astrocytes, Microglia and NeuronsNeuroimmunomodulation, 1996